Pharmacokinetics and Toxicology of Cyclodextrins

  • Karl-Heinz Frömming
  • József Szejtli
Part of the Topics in Inclusion Science book series (TISC, volume 5)

Abstract

One of the remarkable properties of CDs is their outstanding resistance towards the usual starch hydrolyzing enzymes. They are completely resistant to β-amylase since they do not contain end groups susceptible to the attack of this enzyme. Since they attack inside the molecules and do not require free end groups, α-amylases are capable of hydrolyzing the CDs, though usually at a low rate.

Keywords

Allergic Contact Dermatitis Haemolytic Activity Colon Microflora Proximal Tubuli Haemolytic Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anderson W. R., Calderwood-Mais M., Brewster M. and Bodor N.: Minutes of the 6th International Symposium on Cyclodextrins (Chicago), Editions de Santé, Paris, p. 288 (1992).Google Scholar
  2. Antenucci R. N. and Palmer J. K.: J. Agric. Food Chem. 32, 1316 (1984).CrossRefGoogle Scholar
  3. Antlsperger G.: Minutes of the 6th International Symposium on Cyclodextrins (Chicago), Editions de Santé, Paris, p. 277 (1992).Google Scholar
  4. Brewster M. E. in: New Trends in Cyclodextrins and Derivatives (Ed.: Duchêne D. ), Editions de Santé, Paris (1991).Google Scholar
  5. Gerlóczy A., Fónagy A., Keresztes P., Perlaky L. and Szejtli J.: Arzneim. Forsch. (Drug. Res.) 35, 1042 (1985).Google Scholar
  6. Irie T., Otagiri M., Sunada M., Uekama K., Ohtani Y., Yamada Y. and Sugiyama Y.: J. PharmacobioDyn. 5, 741 (1982).PubMedCrossRefGoogle Scholar
  7. Mesens J. L., Putteman P. and Verheyen P. in: New Trends in Cyclodextrins and Derivatives (Ed.: Duchêne D. ), Editions de Santé, Paris (1991).Google Scholar
  8. Pitha J. in: New Trends in Cyclodextrins and Derivatives (Ed.: Duchêne D. ), Editions de Santé, Paris (1991).Google Scholar
  9. Seiyama A., Yoshida N. and Fujimoto M.: J. Incl. Phenom. 2, 765 (1984).CrossRefGoogle Scholar
  10. Strattan C. E.: Pharm. Techn. Int. 39, May (1992).Google Scholar
  11. Szejtli J. in: Cyclodextrins in their Industrial Uses (Ed.: Duchêne D. ), Editions de Santé, Paris (1987).Google Scholar
  12. Uekama K., Irie T., Sumada M., Otagiri M., Iwasaki K., Okano Y., Miyata T. and Kase Y.: J. Pharm. Pharmacol 33, 707 (1981).PubMedCrossRefGoogle Scholar
  13. Yamamoto M., Aritomi H., Irie T., Hirayama F. and Uekama K.: S.T.P. Pharmacy 1, 397 (1991).Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1994

Authors and Affiliations

  • Karl-Heinz Frömming
    • 1
  • József Szejtli
    • 2
  1. 1.Free UniversityBerlinGermany
  2. 2.CyclolabBudapestHungary

Personalised recommendations